Combination activity of eribulin liposomal formulation and anti-PD-1 antibody after tumor regrowth during anti-PD-1 antibody treatment in mice

被引：0
|
作者：
Tamura, Moe
Niwa, Yuki
Semba, Taro
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5260
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neutralizing anti-FGFR1 antibody as a combined partner of anti-PD-1 antibodies in tumor models
    Tsimafeyeu, I.
    Smith, J.
    Yin, W.
    Fanelli, A.
    Olshanskaya, A.
    Khochenkov, D. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1315 - S1315
  • [42] Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer
    Nesselhut, Jan
    Marx, Dagmar
    Lange, Hans
    Regalo, Goncalo
    Cillien, Nicole
    Chang, Raymond Y.
    Nesselhut, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] The effect of anti-PD-1 antibody for peritoneal metastasis of gastric cancer in immunocompetent mice
    Kumagai, Yuko
    Miyato, Hideyo
    Ohzawa, Hideyuki
    Sakuma, Yasunari
    Horie, Hisanaga
    Hosoya, Yoshinori
    Sata, Naohiro
    Kitayama, Joji
    CANCER SCIENCE, 2021, 112 : 360 - 360
  • [44] Tumor suppressive effect of anti-PD-1 antibody against angiosarcoma in a mouse model
    Sekiguchi, Akiko
    Ishikawa, Mai
    Fujiwara, Chisako
    Inoue, Yuta
    Yamazaki, Sahori
    Uchiyama, Akihiko
    Motegi, Sei-ichiro
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2022, 105 (01) : 58 - 60
  • [45] Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takuya
    Hachiga, Kosuke
    Shichino, Shigeyuki
    Terashima, Yuya
    Toda, Etsuko
    Shand, Francis H. W.
    Kakimi, Kazuhiro
    Ito, Satoru
    Matsushima, Kouji
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) : 631 - 640
  • [46] Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer
    Wang, Yuanyuan
    Wei, Bin
    Gao, Jianhua
    Cai, Xiaomin
    Xu, Lingyan
    Zhong, Haiqing
    Wang, Binglin
    Sun, Yang
    Guo, Wenjie
    Xu, Qiang
    Gu, Yanhong
    JOURNAL OF IMMUNOLOGY, 2020, 205 (10): : 2905 - 2915
  • [47] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Su, Xin
    Li, Jian
    Xu, Xiao
    Ye, Youbao
    Wang, Cailiu
    Pang, Guanglong
    Liu, Wenxiu
    Liu, Ang
    Zhao, Changchun
    Hao, Xiangyong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [48] Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models
    Linn, Douglas E.
    Cristescu, Razvan
    Ray, Kallol
    Zhang, Shuli
    Dhandapani, Sripriya
    Kaliyaperumal, Sarav
    Yearley, Jennifer H.
    Long, Brian J.
    CANCER RESEARCH, 2017, 77
  • [49] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
    Korman, Alan
    Chen, Bing
    Wang, Changyu
    Wu, Linda
    Cardarelli, Pina
    Selby, Mark
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [50] Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment
    Hardcastle, Jayson
    Mills, Lisa
    Malo, Courtney S.
    Jin, Fang
    Kurokawa, Cheyne
    Geekiyanage, Hirosha
    Schroeder, Mark
    Sarkaria, Jann
    Johnson, Aaron J.
    Galanis, Evanthia
    NEURO-ONCOLOGY, 2017, 19 (04) : 493 - 502
12345